OpenScience.ink

2 weeks ago • Nutrition, metabolism, and cardiovascular diseases : NMCD

Heart disease outcomes linked to semaglutide and tirzepatide in type 2 diabetes and obesity: a comprehensive reviewCoronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.

2 weeks ago • medRxiv : the preprint server for health sciences

GLP Medications and Risk of Severe Long COVID in People with Type 2 DiabetesGLP Medications and Severe Post-COVID-19 Outcomes Among Individuals with Type 2 Diabetes Mellitus.

2 weeks ago • Frontiers in endocrinology

Heart protection from incretin therapies beyond diabetes: evidence, how they work, and new treatment options from GLP-1 drugs to combined therapiesIncretin-based cardiovascular protection beyond diabetes: evidence, mechanisms, and therapeutic frontiers from GLP-1 receptor agonists to multi-agonist therapy.

🎖️ Top 10% Journal

2 weeks ago • Nutrition, metabolism, and cardiovascular diseases : NMCD

Using semaglutide to manage heart disease in overweight and obese patients: expert adviceManagement of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use.

2 weeks ago • Surgical endoscopy

Changes in weight-loss surgery use after semaglutide and tirzepatide became popularEvolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide.

📖 Top 20% Journal

2 weeks ago • Cell reports

Modified GLP1R activators favor G protein signaling by shifting a specific outer receptor loopN-terminally modified GLP1R agonists drive G protein bias via extracellular loop 3 displacement.

🥈 Top 2% Journal

2 weeks ago • Cureus

Urinary Problems Linked to Severe Obesity and How Weight Loss Surgery and Diabetes Drugs May Help Manage ThemUrological Complications of Morbid Obesity and the Role of Bariatric Surgery and Glucagon-Like Peptide-1 Receptor Agonists in Their Management: A Systematic Review.

2 weeks ago • Diabetologia

Drug treatment for metabolic dysfunction-associated fatty liver diseasePharmacological treatment of MASH.

🥈 Top 2% Journal

2 weeks ago • Journal of the American Heart Association

🥉 Top 5% Journal

2 weeks ago • JAMA health forum

Compounded GLP-1 Receptor Agonist Use After Shortages in Two States with Likely High DemandPostshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand.

🥉 Top 5% Journal

2 weeks ago • Cureus

Genetic Study Across Populations Links a Blood Sugar Regulator to Antipsychotic Drug Metabolic RisksMulti-ancestry Transcriptome-Wide Association Study (TWAS)-Informed Prioritization of Antipsychotic Metabolic Risk: Evaluation of GLP1R as a Shared Mechanistic Link.

2 weeks ago • BMC endocrine disorders

Short-term tirzepatide treatment and its link to average platelet size in people with obesityEffect of short-term tirzepatide treatment on mean platelet volume in patients with obesity: a retrospective controlled study.

📖 Top 20% Journal

2 weeks ago • The Journal of clinical endocrinology and metabolism

GLP1R gene variations are linked to insulin release and sensitivity in obese children and teensGLP1R haplotypes are associated with insulin secretion and sensitivity in children and adolescents with obesity.

🥉 Top 5% Journal

2 weeks ago • Journal of translational medicine

Tirzepatide as a treatment for kidney problems in obesity: findings from real-world useTirzepatide as a therapeutic tool for kidney impairment in obesity: insights from a real-world study.

🥉 Top 5% Journal

2 weeks ago • Current opinion in HIV and AIDS

New findings and treatment considerations for using glucagon-like peptide-1 drugs in older people with HIVGlucagon-like peptide-1 receptor agonists in the aging population of people with HIV: emerging evidence and clinical implications.

2 weeks ago • British journal of clinical pharmacology

Semaglutide compared to liraglutide and their links to diabetes and heart disease in real-world dataSemaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.

📖 Top 20% Journal

2 weeks ago • Circulation research

Protecting the Heart by Preventing Blood Vessel Aging with GLP-1 Receptor AgonistsPrevention of Vascular Aging as a Novel Paradigm for GLP-1 Receptor Agonist-Mediated Cardioprotection.

🥇 Top 1% Journal

2 weeks ago • Circulation research

GLP-1 Receptor Agonists: From Effective Treatments to Understanding How They WorkGLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight.

🥇 Top 1% Journal

2 weeks ago • RMD open

Potential role of GLP-1 receptor agonists in treating systemic lupus erythematosusGLP-1 receptor agonists in systemic lupus erythematosus: a scoping review.

🎖️ Top 10% Journal

2 weeks ago • Frontiers in endocrinology

Tirzepatide and lower risk of blood clots in lungs and veins: a U.S. multi-center studyTirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study.

🎖️ Top 10% Journal

2 weeks ago • Oral surgery, oral medicine, oral pathology and oral radiology

Mouth and face side effects linked to diabetes drugs called GLP-1 receptor agonists: a global real-world studyOrofacial adverse events associated with Glucagon-like peptide-1 receptor agonists: a real-world multinational retrospective matched cohort study.

📖 Top 50% Journal

2 weeks ago • Biological psychiatry

How GLP-1 Influences Alcohol-Related Behaviors in Animal StudiesGLP-1 and Alcohol-Related Behaviors: Insights From Preclinical Studies.

🥈 Top 2% Journal

3 weeks ago • Skin appendage disorders

Using GLP-1 Receptor Agonists to Treat Hidradenitis Suppurativa and Overall Patient HealthGLP-1 Receptor Agonists in Hidradenitis Suppurativa: Time to Treat the Whole Patient.

📖 Top 50% Journal

3 weeks ago • Cureus

Cellulite as a Possible Sign of Metabolic Problems: Rethinking Body Changes with New Treatments Targeting Glucagon-Like Peptide-1Cellulite as a Possible Biomarker of Metabolic Dysfunction: Redefining Body Remodeling in the Glucagon-Like Peptide-1 Era Through the Cellulite Removal Medical Protocol-G21 Concept.

3 weeks ago • bioRxiv : the preprint server for biology

Separate processing of body signals in the brain's area that controls vomiting and blood pressureFunctional segregation of body-brain signals in the area postrema.

3 weeks ago • Journal of clinical medicine

Comparing GLP-1 or GLP-1/GIP Drugs with SGLT2 Inhibitors in Patients with Irregular Heartbeat and Preserved Heart FunctionGLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis.

📖 Top 20% Journal

3 weeks ago • International journal of molecular sciences

Low Gut Hormones and Tirzepatide as a Multi-Target Approach in Hard-to-Treat Endometriosis Linking Metabolism, Immunity, Tissue Scarring, and PainPeritoneal Incretin Deficiency and Tirzepatide as a Multi-Axis Adjuvant Hypothesis in Treatment-Refractory Endometriosis: A Mechanistic Framework Linking Metabolism, Immunity, Fibrosis, and Nociception.

📖 Top 20% Journal

3 weeks ago • International journal of molecular sciences

Possible Benefits of Glucagon-like Peptide-1 Receptor Drugs for Breathing ProblemsTherapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Respiratory Disorders.

📖 Top 20% Journal

3 weeks ago • Nutrients

Preventing and Managing Iron Deficiency Linked to Treatments That Boost Incretin HormonesIroning Out Possible Micronutrient Deficiencies Associated with Incretin Receptor Agonist-Based Therapies: Proposed Practical Strategies to Prevent and Manage Iron Deficiency.

🎖️ Top 10% Journal

3 weeks ago • Frontiers in endocrinology

Latent autoimmune diabetes in two young women treated with oral semaglutide and long-acting insulinCase Report: Latent autoimmune diabetes in two young female patients successfully treated with oral semaglutide and basal insulin.

🎖️ Top 10% Journal

← prevpage 9 of 15next →

Latest GLP-1 Therapies Research Papers